Technology-Assisted Interventions for Smoking Cessation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two methods to help people quit smoking, particularly those receiving medical care for cancer prevention. One method uses a standard approach, while the other adds extra support with nudges to encourage quitting. The methods being tested are called ELEVATE and ELEVATE-S. Adults who use tobacco and receive care at a participating clinic might be suitable candidates. The goal is to determine which method more effectively helps people quit smoking. As an unphased trial, this study provides a unique opportunity to contribute to research that could improve smoking cessation strategies for many.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these technology-assisted interventions are safe for smoking cessation?
Research has shown that the medications used in the ELEVATE program to help people quit smoking do not increase the risk of serious heart problems. These treatments have undergone studies for heart safety and are generally well-tolerated.
For ELEVATE-S, which may use electronic methods to aid smoking cessation, electronic cigarettes and similar devices have been researched. Some studies suggest they can help people stop smoking, but known risks exist, especially for young people and adults.
Overall, both methods aim to help people quit smoking, and past research suggests they are safe for humans, with some manageable side effects.12345Why are researchers excited about this trial?
Researchers are excited about the ELEVATE and ELEVATE-S interventions for smoking cessation because they harness the power of electronic health records to deliver personalized, evidence-based tobacco treatments. Unlike traditional methods like nicotine replacement therapy or counseling, these interventions integrate seamlessly into healthcare systems, allowing for customized support and tracking of patient progress in real-time. This innovative approach could improve accessibility and effectiveness, making it easier for individuals to quit smoking with tailored support.
What evidence suggests that this trial's treatments could be effective for smoking cessation?
Studies have shown that ELEVATE, one of the treatments in this trial, significantly increases the number of smokers who receive help to quit. Before ELEVATE, only 1.6% of smokers received treatment to stop smoking, but this rose to 27.9% after the program began. The success rate for quitting smoking also improved from 12.0% to 17.2%. Quitting smoking, especially after a cancer diagnosis, can greatly improve survival chances. ELEVATE-S, another treatment option in this trial, builds on these methods by offering extra support, which could further enhance the chances of quitting successfully.678910
Who Is on the Research Team?
Li-Shiun Chen, M.D., MPH, ScD
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults over 18 who currently use tobacco and are receiving care at a participating clinic. They must have completed an appointment with the clinic to qualify. The study aims to help them quit smoking by comparing two strategies.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tobacco use treatment through either ELEVATE or ELEVATE-S strategies
Follow-up
Participants are monitored for smoking cessation and treatment effectiveness
What Are the Treatments Tested in This Trial?
Interventions
- ELEVATE
- ELEVATE-S
Trial Overview
The CONNECT trial is testing two different methods to help cancer survivors stop smoking: ELEVATE, which is usual care focused on quitting, and ELEVATE-S, which includes additional 'nudges' or prompts designed to increase tobacco treatment uptake.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Citations
Increased Reach and Effectiveness with a Low-Burden ...
ELEVATE, a low-burden point-of-care intervention, was associated with increased reach and effectiveness of smoking cessation treatment.
Increased Reach and Effectiveness With a Low-Burden Point ...
Results: The proportion of current tobacco smokers receiving cessation treatment increased from pre-ELEVATE to post-ELEVATE (1.6%-27.9%; difference, 26.3%; ...
3.
translationalsciencebenefits.wustl.edu
translationalsciencebenefits.wustl.edu/case-study/advancing-equitable-treatment-for-smoking-cessation-in-cancer-patients/Advancing Equitable Treatment for Smoking Cessation in ...
Additionally, ELEVATE increased the effectiveness of patient smoking cessation from 12.0% to 17.2%. ELEVATE addresses equity in many ways.
4.
renalandurologynews.com
renalandurologynews.com/news/quitting-smoking-following-cancer-diagnosis-improves-survival-study-suggests/Quitting Smoking Following Cancer Diagnosis Improves ...
Smoking cessation after cancer diagnosis is linked to improved overall survival even for advanced cancers, according to a recent study.
Contingency management for smoking cessation among ...
This study aims to examine the effect of CM on smoking outcomes and in-treatment behaviors (i.e., retention, session attendance and adherence to nicotine use ...
6.
evotec.com
evotec.com/news/evotec-reports-phase-i-safety-data-from-tyramine-interaction-study-with-evt-302Evotec Reports Phase I Safety Data from Tyramine Interaction ...
At the highest EVT 302 dose tested (>5 fold the expected therapeutic dose), a small increase in tyramine sensitivity was produced, which was within the range of ...
Cardiovascular Safety of Varenicline, Bupropion, and ...
The findings of EAGLES and its extension trial provide further evidence that smoking cessation medications do not increase the risk of serious ...
Public Health Impact of FDA's Request for Additional Safety ...
We applied a 10% probability of smoking relapse after 1 year of abstinence. For life expectancy gains from smoking cessation at different ages ( ...
Evaluation of the safety profile of an electronic vapour ...
The most frequently reported AEs were headache, nasopharyngitis, sore throat and cough, reported by 28.7%, 28.7%, 19.6% and 16.7% of subjects, respectively, ...
HHS Framework to Support and Accelerate Smoking ...
This longitudinal cohort study, launched in 2011 and ongoing, provides data on tobacco use behaviors, attitudes and beliefs, and tobacco-related outcomes. • NIH ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.